(BTSG) BrightSpring Health - Overview

Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 8.279m USD | Total Return: 160.4% in 12m

Home Health, Pharmacy, Therapy, Behavioral
Total Rating 63
Safety 68
Buy Signal 0.73
Health Information Services
Industry Rotation: -24.5
Market Cap: 8.28B
Avg Turnover: 108M USD
ATR: 4.24%
Peers RS (IBD): 95.0
Risk 5d forecast
Volatility44.1%
Rel. Tail Risk-6.16%
Reward TTM
Sharpe Ratio2.25
Alpha125.17
Character TTM
Beta1.380
Beta Downside1.564
Drawdowns 3y
Max DD35.56%
CAGR/Max DD2.56
EPS (Earnings per Share) EPS (Earnings per Share) of BTSG over the last years for every Quarter: "2021-03": null, "2021-06": null, "2021-09": null, "2021-12": null, "2022-03": null, "2022-06": null, "2022-09": null, "2022-12": null, "2023-03": null, "2023-06": null, "2023-09": null, "2023-12": 0.14, "2024-03": 0.12, "2024-06": 0.1, "2024-09": 0.11, "2024-12": 0.22, "2025-03": 0.19, "2025-06": 0.13, "2025-09": 0.17, "2025-12": 0.33,
EPS CAGR: 53.53%
EPS Trend: 66.5%
Last SUE: 1.16
Qual. Beats: 1
Revenue Revenue of BTSG over the last years for every Quarter: 2021-03: 1514.449, 2021-06: 1645.978, 2021-09: 1736.156, 2021-12: 1801.499, 2022-03: 1884.2545, 2022-06: 1884.2545, 2022-09: 1981.415, 2022-12: 1970.636, 2023-03: 2028.378, 2023-06: 2166.724, 2023-09: 2256.529, 2023-12: 2374.544, 2024-03: 2285.766, 2024-06: 2438.254, 2024-09: 2906.823, 2024-12: 3052.801, 2025-03: 2878.129, 2025-06: 3147.698, 2025-09: 3334.106, 2025-12: 3550.631,
Rev. CAGR: 18.41%
Rev. Trend: 97.7%
Last SUE: 1.30
Qual. Beats: 4

Warnings

P/E ratio 89.8

High Debt/EBITDA (6.0) with thin interest coverage (1.9)

Tailwinds

Watch

Description: BTSG BrightSpring Health

BrightSpring Health Services, Inc. (BTSG) delivers home and community-based healthcare. This model addresses the growing preference for care outside traditional institutional settings, often driven by an aging population and advancements in home healthcare technology.

The company operates in two segments: Pharmacy Solutions and Provider Services. Pharmacy services include infused, injectable, and oral medications. Provider services encompass clinical home health care, rehabilitation (physical, speech, occupational therapy), and applied behavioral analysis. These services cater to Medicare, Medicaid, and commercially insured populations, reflecting the diverse funding landscape within the healthcare sector.

Founded in 1974 and headquartered in Louisville, Kentucky, BrightSpring Health Services, Inc. was formerly known as Phoenix Parent Holdings Inc. Further research on ValueRay can provide deeper insights into the companys financial performance and market position.

Headlines to Watch Out For
  • Medicaid and Medicare reimbursement rates impact revenue
  • Home health services demand drives growth
  • Pharmacy solutions segment contributes to revenue
  • Regulatory changes in healthcare sector pose risk
  • Labor costs for skilled healthcare professionals affect profitability
Piotroski VR‑10 (Strict) 4.0
Net Income: 190.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA 8.61 > 1.0
NWC/Revenue: 8.09% < 20% (prev 4.35%; Δ 3.74% < -1%)
CFO/TA 0.08 > 3% & CFO 490.2m > Net Income 190.7m
Net Debt (2.75b) to EBITDA (459.5m): 5.99 < 3
Current Ratio: 1.57 > 1.5 & < 3
Outstanding Shares: last quarter (219.8m) vs 12m ago 3.10% < -2%
Gross Margin: 11.76% > 18% (prev 0.13%; Δ 1.16k% > 0.5%)
Asset Turnover: 209.3% > 50% (prev 180.3%; Δ 28.98% > 0%)
Interest Coverage Ratio: 1.88 > 6 (EBITDA TTM 459.5m / Interest Expense TTM 157.3m)
Altman Z'' 1.33
A: 0.16 (Total Current Assets 2.89b - Total Current Liabilities 1.85b) / Total Assets 6.41b
B: -0.01 (Retained Earnings -74.6m / Total Assets 6.41b)
C: 0.05 (EBIT TTM 295.3m / Avg Total Assets 6.17b)
D: -0.02 (Book Value of Equity -79.4m / Total Liabilities 4.53b)
Altman-Z'' Score: 1.33 = BB
Beneish M -3.14
DSRI: 0.71 (Receivables 989.7m/1.15b, Revenue 12.91b/10.68b)
GMI: 1.14 (GM 11.76% / 13.43%)
AQI: 0.82 (AQ_t 0.49 / AQ_t-1 0.60)
SGI: 1.21 (Revenue 12.91b / 10.68b)
TATA: -0.05 (NI 190.7m - CFO 490.2m) / TA 6.41b)
Beneish M-Score: -3.14 (Cap -4..+1) = AA
What is the price of BTSG shares? As of April 12, 2026, the stock is trading at USD 45.33 with a total of 1,413,777 shares traded.
Over the past week, the price has changed by +4.18%, over one month by +9.65%, over three months by +16.20% and over the past year by +160.37%.
Is BTSG a buy, sell or hold? BrightSpring Health has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy BTSG.
  • StrongBuy: 9
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the BTSG price?
Analysts Target Price 52.6 16%
BrightSpring Health (BTSG) - Fundamental Data Overview as of 12 April 2026
P/E Trailing = 89.7917
P/E Forward = 40.6504
P/S = 0.6412
P/B = 4.4157
Revenue TTM = 12.91b USD
EBIT TTM = 295.3m USD
EBITDA TTM = 459.5m USD
Long Term Debt = 2.46b USD (from longTermDebt, last quarter)
Short Term Debt = 102.1m USD (from shortTermDebt, last quarter)
Debt = 2.84b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.75b USD (from netDebt column, last quarter)
Enterprise Value = 11.03b USD (8.28b + Debt 2.84b - CCE 88.4m)
Interest Coverage Ratio = 1.88 (Ebit TTM 295.3m / Interest Expense TTM 157.3m)
EV/FCF = 22.51x (Enterprise Value 11.03b / FCF TTM 490.2m)
FCF Yield = 4.44% (FCF TTM 490.2m / Enterprise Value 11.03b)
FCF Margin = 3.80% (FCF TTM 490.2m / Revenue TTM 12.91b)
Net Margin = 1.48% (Net Income TTM 190.7m / Revenue TTM 12.91b)
Gross Margin = 11.76% ((Revenue TTM 12.91b - Cost of Revenue TTM 11.39b) / Revenue TTM)
Gross Margin QoQ = 11.62% (prev 11.76%)
Tobins Q-Ratio = 1.72 (Enterprise Value 11.03b / Total Assets 6.41b)
Interest Expense / Debt = 1.36% (Interest Expense 38.5m / Debt 2.84b)
Taxrate = 28.78% (20.0m / 69.6m)
NOPAT = 210.3m (EBIT 295.3m * (1 - 28.78%))
Current Ratio = 1.57 (Total Current Assets 2.89b / Total Current Liabilities 1.85b)
Debt / Equity = 1.52 (Debt 2.84b / totalStockholderEquity, last quarter 1.88b)
Debt / EBITDA = 5.99 (Net Debt 2.75b / EBITDA 459.5m)
Debt / FCF = 5.62 (Net Debt 2.75b / FCF TTM 490.2m)
Total Stockholder Equity = 1.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.09% (Net Income 190.7m / Total Assets 6.41b)
RoE = 10.71% (Net Income TTM 190.7m / Total Stockholder Equity 1.78b)
RoCE = 6.97% (EBIT 295.3m / Capital Employed (Equity 1.78b + L.T.Debt 2.46b))
RoIC = 4.89% (NOPAT 210.3m / Invested Capital 4.30b)
WACC = 8.32% (E(8.28b)/V(11.12b) * Re(10.84%) + D(2.84b)/V(11.12b) * Rd(1.36%) * (1-Tc(0.29)))
Discount Rate = 10.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.30%
[DCF] Terminal Value 69.24% ; FCFF base≈490.2m ; Y1≈321.8m ; Y5≈147.2m
[DCF] Fair Price = 0.04 (EV 2.76b - Net Debt 2.75b = Equity 7.70m / Shares 192.1m; r=8.32% [WACC]; 5y FCF grow -40.0% → 3.0% )
 [DCF] Fair Price = 0.04 (out of range, set to none)
 EPS Correlation: 66.50 | EPS CAGR: 53.53% | SUE: 1.16 | # QB: 1
Revenue Correlation: 97.70 | Revenue CAGR: 18.41% | SUE: 1.30 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.36 | Chg7d=+0.001 | Chg30d=-0.013 | Revisions Net=+8 | Analysts=14
EPS current Year (2026-12-31): EPS=1.55 | Chg7d=+0.002 | Chg30d=+0.048 | Revisions Net=+13 | Growth EPS=+55.5% | Growth Revenue=+15.0%
EPS next Year (2027-12-31): EPS=1.95 | Chg7d=+0.010 | Chg30d=+0.256 | Revisions Net=+11 | Growth EPS=+25.7% | Growth Revenue=+12.6%
[Analyst] Revisions Ratio: +1.00 (8 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 9.7% (Discount Rate 10.8% - Earnings Yield 1.1%)
[Growth] Growth Spread = +5.1% (Analyst 14.8% - Implied 9.7%)
External Resources
Dataroma Stockcircle